OR WAIT null SECS
The work will focus on addressing a key bottleneck to progress: he complexity and instability of HIV envelope proteins, which has limited the amount of material that can be evaluated in clinical trials.
A $98-million, seven-year contract will fund work to improve manufacturing, at the International AIDS Vaccine Initiative
The US National Institutes of Health’s National Institute of Allergy and Infectious Diseases, has awarded the International AIDS Vaccine Initiative (IAVI) a $98-million, seven-year contract to help speed the development of AIDS vaccine candidates.
The contract covers a range of product development services to advance the characterization and manufacturing of HIV envelope protein immunogens, which has been a focus of IAVI’s research efforts.
Manufacturing of these immunogens has proven difficult, given the complexity and instability of HIV envelope proteins. This has limited the amount of material that can be evaluated in clinical trials. Optimizing HIV vaccine manufacturing would accelerate the development and evaluation of promising candidates.
IAVI and NIAID have been partnering closely in AIDS vaccine research for many years, including in the design and development of HIV envelope immunogens designed to trigger protective antibody responses.